Why this distinction matters more than ever

For companies developing ingredients for the U.S. market, one question comes up early—and often:

Should this ingredient go the GRAS route, or require an NDI notification?

At a glance, both pathways exist to demonstrate safety under FDA oversight. But in practice, they serve very different regulatory functions, apply to different product categories, and carry different strategic implications.

Choosing incorrectly doesn’t just create delays—it can lead to:

• Regulatory rejection
• Reformulation costs
• Market access limitations
• Increased scrutiny from FDA

If you’re looking for a broader overview of ingredient classification (including ODIs and food additives), see our related article:
“GRAS, New Dietary Ingredients (NDIs), Old Dietary Ingredients (ODIs), and Food Additives – Is Your Product Classified Correctly?”

This article focuses specifically on GRAS vs NDI—and how to think about them strategically.

Scope: Where GRAS vs NDI applies

This is not just a regulatory definition issue. It directly impacts:

• Product category (food vs dietary supplement)
• Type of safety evidence required
• Speed to market
• Ability to protect proprietary data
• Future flexibility across markets

At a high level:

• GRAS → Food (and potentially supplements)
• NDI → Dietary supplements only

That distinction drives everything else.

GRAS vs NDI: Side-by-side comparison

Core regulatory differences

*Note that once an ingredient achieves GRAS status and is subsequently marketed in foods, it may be permitted for sale in dietary supplements in a form in which the ingredient has not been chemically altered.

These differences are not just technical—they reflect two fundamentally different regulatory philosophies.

Where the real differences show up

1. Intended use drives everything

The most important distinction is simple:

• If your ingredient is going into food → GRAS is required
• If your ingredient is only for supplements → NDIN may apply

NDINs cannot be used for conventional foods—full stop.

Strategic takeaway:
GRAS is often the more scalable pathway if you plan multi-format product expansion.

2. Public vs proprietary data

This is one of the most overlooked—but critical—differences.

• GRAS requires publicly available evidence and consensus among qualified experts
• NDI allows confidential, proprietary studies

That means:

• GRAS → stronger transparency, but less intellectual property (IP) protection
• NDI → stronger IP protection, but less flexibility

NDI submissions—and especially NDIN Master Files—can centralize proprietary safety, identity, and manufacturing data for reuse across multiple submissions.

Strategic takeaway:
If your competitive advantage depends on proprietary data, an NDIN may be more attractive.

3. Safety standard vs regulatory reality

Typically:

• GRAS sometimes requires a higher safety standard – vulnerable subpopulations need to be considered (i.e. pregnant woman, children, individuals specific sensitivities etc.)
• NDINs require larger safety margins (since dietary exposure is more ‘fixed’ and not based on implied conservative estimations like food products)

But in practice:

• GRAS notifications have higher success rates (~75%)
• NDINs face significant FDA scrutiny and lower acceptance rates (~30%)

This disconnect is driven by:

• FDA familiarity with GRAS evaluations
• Increasing expectations for NDIN completeness and justification

Strategic takeaway:
NDI is not necessarily the “easier” pathway—even if it may appear that way at face value.

4. Regulatory process and timelines

GRAS

• Can be self-affirmed (review by independently verified expert panel; no FDA submission required)
• Or submitted via GRAS notification
• FDA review: ~180+ days

NDI

• Mandatory notification to FDA
• Must wait 75 days before marketing
• FDA issues acknowledgment or objection

Unlike GRAS, NDIN submissions must include sufficient evidence that the ingredient is reasonably expected to be safe under the labeled conditions of use.

Strategic takeaway:
NDI has a shorter timeline—but more regulatory dependency.

5. Flexibility across the product lifecycle

GRAS offers a major advantage:

• Can support food + supplement applications
• Enables broader commercial use cases
• Aligns with less burdensome food GMP requirements

NDI is more constrained:

• Limited to supplements
• Subject to stricter supplement GMPs
• Often requires reformulation for food use

Strategic takeaway:
GRAS is typically the better long-term play for scalable ingredient commercialization, as long as there is an intention to market the product in at least one category of conventional foods and or/beverages.

What GRAS and NDI have in common

Despite their differences, both pathways share core expectations:

• Same regulator: U.S. FDA
• Same goal: Demonstrate safety
• Same scientific foundation:
  • Identity & composition
  • Manufacturing process
  • Exposure assessment
  • Toxicology data

Both ultimately require a defensible safety narrative backed by scientific evidence.

How to decide: GRAS vs NDI

The decision should not be made in isolation—it should align with your product strategy, data availability, and commercialization goals.

GRAS is typically better when:

• You are targeting conventional foods and/or beverages
• There is strong published safety data
• You want broad market flexibility
• You do not need subpopulation restrictions

NDI is typically required or preferred when:

• The ingredient is new (post-1994)
• It will only be used in supplements
• You wish to rely on proprietary data
• You prefer to have label-based population restrictions

In many cases, companies evaluate both pathways in parallel before deciding.

The bigger picture: It’s not just GRAS vs NDI

GRAS and NDI are only part of a broader classification framework that also includes:

• Old Dietary Ingredients (ODIs)
• Food Contact Materials
• General Ingredient classification strategies

For a full breakdown, refer to:
“GRAS, New Dietary Ingredients (NDIs), Old Dietary Ingredients (ODIs), and Food Additives – Is Your Product Classified Correctly?”

This ensures your product is not just compliant—but correctly positioned from the start.

Conclusion: GRAS vs NDI is a strategic decision

GRAS vs NDI is often framed as a regulatory choice.

In reality, it’s a business and commercialization decision.

• GRAS offers flexibility, scalability, and broader market access
• NDI offers confidentiality and targeted supplement use

Both can be valid—but only one will align with your product strategy.

The key is not just understanding the difference—but choosing the right pathway early.

How dicentra can help

At dicentra, we support companies across:

• GRAS determinations and notifications
• NDI strategy and NDIN submissions
• NDIN Master File development and cross-referencing
• Ingredient classification and regulatory positioning

We help you align regulatory strategy with commercial goals—so you don’t just meet requirements, you move faster and with confidence.

Talk to our team about your GRAS vs NDI strategy →